L Maattanen
Overview
Explore the profile of L Maattanen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaapu K, Murtola T, Maattanen L, Talala K, Taari K, Tammela T, et al.
Cancer Causes Control
. 2015 Nov;
27(2):157-64.
PMID: 26573846
Purpose: Long-term usage of the antiarrhythmic drug digoxin has been connected to lowered risk of prostate cancer. A recent study has suggested that beta-blockers might also have similar risk-decreasing effects....
2.
Veitonmaki T, Murtola T, Maattanen L, Taari K, Stenman U, Tammela T, et al.
Br J Cancer
. 2014 Jul;
111(7):1421-31.
PMID: 25010865
Background: The association between nonsteroidal antiinflammatory drugs (NSAIDs) and prostate cancer risk remains controversial. We examined the risk among NSAID users in 78 615 men in the Finnish Prostate Cancer...
3.
Laurila M, van der Kwast T, Bubendorf L, Di Lollo S, Pihl C, Ciatto S, et al.
Eur J Cancer
. 2010 Nov;
46(17):3068-72.
PMID: 21047588
The Aim Of The Study: This article presents the incidence of prostate cancer, isolated high grade prostatic intraepithelial neoplasia (PIN) and atypical lesions suspicious for prostate cancer (LSPC) during subsequent...
4.
Otto S, Moss S, Maattanen L, Roobol M, Zappa M, Nelen V, et al.
Eur J Cancer
. 2010 Nov;
46(17):3053-60.
PMID: 21047586
Background: To describe the variation in PSA level by age group and screening round in the ERSPC centres and the variation in cancer detection rates in relation to the underlying...
5.
Kilpelainen T, Tammela T, Maattanen L, Kujala P, Stenman U, Ala-Opas M, et al.
Br J Cancer
. 2010 Jan;
102(3):469-74.
PMID: 20051951
Background: There is evidence that prostate cancer (PC) screening with prostate-specific antigen (PSA) serum test decreases PC mortality, but screening has adverse effects, such as a high false-positive (FP) rate....
6.
Murtola T, Tammela T, Maattanen L, Ala-Opas M, Stenman U, Auvinen A
Br J Cancer
. 2009 Aug;
101(5):843-8.
PMID: 19654575
Background: The Prostate Cancer Prevention Trial has shown a protective effect of finasteride on prostate cancer in low-risk men. It is uncertain whether similar results can be expected when finasteride...
7.
Maattanen L, Hakama M, Tammela T, Ruutu M, Ala-Opas M, Juusela H, et al.
Br J Cancer
. 2007 Jan;
96(1):56-60.
PMID: 17213825
Specificity constitutes a component of validity for a screening test. The number of false-positive (FP) results has been regarded as one of major shortcomings in prostate cancer screening. We estimated...
8.
Roobol M, Zappa M, Maattanen L, Ciatto S
Prostate
. 2006 Dec;
67(4):439-46.
PMID: 17192912
Background: Although serum PSA testing is widely used as a screening test for prostate cancer (PC), it is known that it is not specific for PC. The study described here...
9.
Finne P, Stenman U, Maattanen L, Makinen T, Tammela T, Martikainen P, et al.
BJU Int
. 2004 Feb;
92 Suppl 2:22-6.
PMID: 14983949
No abstract available.
10.
Miller A, Madalinska J, Church T, Crawford D, Essink-Bot M, Goel V, et al.
Eur J Cancer
. 2001 Oct;
37(17):2154-60.
PMID: 11677101
Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the...